University of Notre Dame Patent applications |
Patent application number | Title | Published |
20150072878 | Stratification of Left-Side and Right-Side Colon Cancer - Compositions/methods for employing fresh-frozen or FFPE colon cancer tissue in left side colon cancer (LCC) and right-side colon cancer (RCC) disease patients for risk of relapse assessment/stratification is provided (3 strata and a 4 strata methodology). An RCC gene panel of 4 genes (FAM69A, CDX2, FAM84A, ITGA3), and 9 genes (FAM69A, CDX2, ITGA3, FAM84A, ITPRIP, RAB3B, SMAD3, PCSK5, MMP28), is provided. An LCC gene panel of 4 genes (NOX4, WNT5A, MMP3, IBSP), and a 9 genes (MMP3, WINT5A, NOX4, IBSP, SLC16A6, CYPIBI, TFAP2C, MATN3, ANKRD6), is provided. A microchip-based clinical tool, and a kit including a microchip, is presented. The invention also describes a computer-implemented method for assessing relative risk of relapse in LCC and/or RCC disease. An individual patient scoring method that presents a continuous stratification score useful in the post-surgical colon cancer management of LCC and/or RCC patient is also presented. | 03-12-2015 |
20140341809 | High-Affinity DMF5 T Cell Receptor (TCR) Variants - High-affinity variants of the DMF5 TCR, and methods of use thereof for the treatment and imaging of cancer in a patient. | 11-20-2014 |
20130203066 | METHOD FOR DETECTING INVASIVE MICROVESCLES DERIVED FROM TUMOR CELLS - The present application relates to the isolation and analysis of populations of microvesicles and the identification of invasive microvesicles in the populations such as populations of microvesicles that are shed by tumor cells. Invasive microvesicles from tumor cells contain a variety of specific proteins, such as ARF6. | 08-08-2013 |
20120278913 | Ribozyme Effector Gene in Dengue Fever Transmission and Disease Control - Disclosed are anto-DENV ribozyme based methods and compositions useful in the inhibition and control of all Dengue fever serotypes (designated DENV 1 through 4). A group of anti-DENV Group 1 trans-splicing introns (αDENV-GrpIa) are presented that target DENV-2 NGC genomes in situ. Methods for specifically targeting a highly conserved 5′-3′ cyclization sequence (CS) region that is common to all serotypes of the DENV are provided. The anti-DENV Group 1 trans-splicing introns (αDENV-GrpIa) specifically target two different uracil bases on the positive sense genomic strand. The invention provides an RNA based approach for transgeneic suppression of DENV in transformed mosquitoes using a group of specifically designed introns that trans-splice a new RNA sequence downstream of a targeted site. The aDENV-GrpIs target DENV infected genomes and thus provide a method for inhibiting the spread of Dengue fever. An αDENV-GrpI 9v1 is presented that is designed to be active against all forms of Dengue virus, and to effectively target the DENV-2 NGC genome in a sequence specific manner | 11-01-2012 |
20120276071 | Anti-HIV Group I Introns and Uses Thereof in Treating HIV Infections - Described is a unique class of antiviral molecule that can be applied to control and eliminate HIV infection in patients using myeloablation therapies and replenishment with transformed bone marrow stem cells programmed to express the antiviral molecule. These anti-viral molecules target the HIV genome in a highly conserved domain, and when expressed in cells prior to infection will cause the cell to die upon infection with HIV. Cell death insures no proliferation of new virus. Reconstituting the immune system with cells expressing these antivirals prevents re-establishment of HIV infection from reservoirs in the re-established lymphocyte and macrophage populations. Over time, reservoirs will be depleted entirely, effectively eliminating the virus. In effect, this new type of antiviral can be used to cure HIV infections. | 11-01-2012 |
20110150934 | Ovarian Tumor Tissue Cell Preparations/Vaccines for the Treatment/Inhibition of Ovarian Tumors and Ovarian Cancer - Disclosed are compositions comprising non-viable ovarian tumor cells and/or ovarian cancer tissue cells useful as a vaccine for human ovarian cancer and/or for the inhibition of human ovarian tumor growth. Methods for preparing the ovarian cancer and/or tumor vaccines that comprise these compositions are also provided, as well as methods of using the vaccines in the treatment and/or inhibition of tumor growth, and particularly ovarian tumor growth and ovarian cancers. The preparations may be defined as vaccines comprising human ovarian tumor tissue cells and/or human ovarian cancer cells. Preparations comprising the ovarian tissue cells together with an adjuvant are also provided. The ovarian tumor and/or ovarian cancer vaccines are demonstrated to significantly reduce the incidence of autochthonous ovarian cancer. | 06-23-2011 |
20110135690 | EXTRACELLULAR MATRIX ADJUVANT & METHODS FOR PREVENTION AND/OR INHIBITION OF OVARIAN TUMORS AND OVARIAN CANCER - Compositions suitable for use as ovarian cancer and/or tumor adjuvants in the preparation of ovarian cancer vaccines, particularly those vaccines useful in the treatment of human ovarian cancer, are provided. The ovarian cancer adjuvants described are comprised of an extracellular matrix material, such as small intestinal submucosal (SIS) tissue. The preparations may take the form of sheets, gels, liquids (injectable), tracer, or other solid or semi-solid preparation. Also disclosed are ovarian tumor inhibiting compositions that include extracellular matrix tissue adjuvants. | 06-09-2011 |
20100221824 | Methods and compositions for transposition using minimal segments of the eukaryotic transformation vector piggyBac - The present invention provides a method for transforming an insect genome that has a much enhanced transformation frequency. The vectors and plasmids employed in the method are further described as transposition vectors that include a minimal amount of nucleotide sequence homologous to a 5′ region and a 3′ region of a native piggyBac nucleic acid sequence. The transformed cells or embryos may also be developed into transgenic organisms. Disclosed are minimal piggyBac-based plasmid constructs that comprises a minimal nucleic acid sequence homologous to a 5′ end of a piggyBac nucleic acid sequence (about 60-80 bp, particularly 66 bp) and a relatively long (300 to about 380 bp, particularly 311 by or 378 bp) continuous nucleic acid sequence homologous to a 3′ end of a piggyBac native nucleic acid sequence. Methods employing these constructs include the use of a helper plasmid. Transformation frequencies employing the constructs are enhanced 100-fold or higher over that transformation frequency obtained using other than the herein described constructs. | 09-02-2010 |
20100196906 | Accelerated Progression Relapse Test - Disclosed is an accelerated progression relapse test for use in the prognosis of disease states. According to the test disclosed herein, it can be determined whether a patient would benefit from treatment for a disease state or whether the patient's prognosis would not have a high probability of benefit with additional treatment. In particular, the test is useful in determining a patient's prognosis for cancer (breast, colon, lung, etc). For example, the test of the invention can be used to determine the prognosis for estrogen receptor positive (ER+) breast cancer patients. In the test for ER+ breast cancer patients, four genetic probes are employed that target MK167, CDC6, and SPAG5 gene products. The ER+ breast cancer test stratifies a patient population into two groups, with the low gene expression group identifying a group that is less likely to benefit from additional treatment measures, and a high gene expression group, identifying a group more likely to benefit from additional treatment measures. | 08-05-2010 |
20090220461 | Metastasis inhibition preparations and methods - Disclosed are compositions and pharmaceutical preparations suitable for inhibiting metastasis of a malignant cancer in an animal. Methods for inhibiting and/or eliminating metastasis in an animal are also provided. In some embodiments, the preparations and compositions comprise a whole cell tumor preparation comprising tumor tissue cells and tumor connective tissue stroma. The disclosure also provides methods for preparing the preparations and pharmaceutical preparations. Inhibition of metastasis of malignant prostate cancer to the lung is shown in vivo. | 09-03-2009 |